A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

Trial Details

NCT ID
NCT06393738
Phase
PHASE1
Sponsor
Arvinas Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • ARV-393
  • Glofitamab
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Miami, Florida, United States|25.77427,-80.19366
  • Detroit, Michigan, United States|42.33143,-83.04575
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • For Part A and B: Have relapsed/refractory NHL and \>=2 prior systemic therapies, (including rituximab), and be ineligible for known therapies with…
  • For Part C and D: Have R/R DLBCL, not otherwise specified \[NOS (DLBCL, NOS)\] or large B-cell lymphoma (LBCL) arising from follicular lymphoma and…
  • Have at least one bi dimensionally measurable lesion \>1.5-centimeter (cm) in largest dimension for nodal or \>1.0 cm for extranodal lesion.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (NOTE: For Part A only - ECOG PS of 2 is allowed for participants with …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →